
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Max Bronstein, CEO, Aviva Strategies Teresa Barnes, Chief Executive Warrior, PF Warriors Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Publisher
BioSpace
Published
October 1, 2026
Duration
20 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
BioSpace
@biospace
#fairact #reclaim #biotechleadership #lifesciences
